Relay Therapeutics (RLAY) Change in Receivables (2021 - 2023)
Relay Therapeutics (RLAY) posted quarterly Change in Receivables of -$211000.0 for Q4 2023, down 424.62% year-over-year from $65000.0 in Q4 2022, and down 258.65% quarter-over-quarter from $133000.0 in Q3 2023.
Relay Therapeutics (RLAY) Change in Receivables (2021 - 2023) Analysis & Trends
Relay Therapeutics (RLAY) has reported Change in Receivables for 3 consecutive years, with -$211000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Change in Receivables fell 424.62% year-over-year to -$211000.0; the TTM figure through Dec 2023 stood at -$306000.0 (down 215.46% YoY), while the FY2023 annual figure was -$306000.0, down 215.46% from the prior year.
- Change in Receivables eased to -$211000.0 in Q4 2023 per RLAY's latest filing, from $133000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $525000.0 in Q3 2021 and bottomed at -$75.0 million in Q1 2021.
- Historically, Change in Receivables has averaged -$6.3 million across 3 years, with a median of -$33500.0 in 2022.
- On a YoY basis, Change in Receivables climbed as much as 382.98% in 2023 and fell as far as 1194.74% in 2023.
- Relay Therapeutics' Change in Receivables stood at -$401000.0 in 2021, then jumped by 116.21% to $65000.0 in 2022, then tumbled by 424.62% to -$211000.0 in 2023.
- Business Quant data shows RLAY's Change in Receivables at -$211000.0 in Q4 2023, $133000.0 in Q3 2023, and -$208000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -211,000.00 |
| Dec 31, 2023 | -211,000.00 |
| Sep 30, 2023 | 133,000.00 |
| Sep 30, 2023 | 133,000.00 |
| Jun 30, 2023 | -208,000.00 |
| Jun 30, 2023 | -208,000.00 |
| Mar 31, 2023 | -20,000.00 |
| Mar 31, 2023 | -20,000.00 |
| Dec 31, 2022 | 65,000.00 |
| Dec 31, 2022 | 65,000.00 |
| Sep 30, 2022 | -47,000.00 |
| Sep 30, 2022 | -47,000.00 |
| Jun 30, 2022 | 19,000.00 |
| Jun 30, 2022 | 19,000.00 |
| Mar 31, 2022 | -134,000.00 |
| Mar 31, 2022 | -134,000.00 |
| Dec 31, 2021 | -401,000.00 |
| Dec 31, 2021 | -401,000.00 |
| Sep 30, 2021 | 525,000.00 |
| Sep 30, 2021 | 525,000.00 |